Fluticasone / salmeterol

Use for asthma inadequately controlled on a long-term controller such as ICS, or when disease warrants both ICS and LABA. Advair Diskus/Wixela: asthma age ≥4; their 250/50 strength also maintains COPD airflow control and reduces exacerbations in patients with exacerbation history. Advair HFA and AirDuo RespiClick: asthma age ≥12; no COPD indication in these labels. None treats acute bronchospasm.

GINA 2026 prefers ICS-formoterol reliever-based Track 1 for adults/adolescents. Maintenance ICS/LABA such as fluticasone/salmeterol is a Track 2 option with separate ICS-SABA reliever, or SABA if unavailable, when MART is not possible or established treatment is stable with adherence. Salmeterol combinations cannot serve as relievers, and ICS-formoterol should not be added as reliever to non-formoterol ICS/LABA maintenance. This is focused asthma guidance, not a complete COPD treatment algorithm.

Oral inhalation only; generally approximately 12 hours apart. Select starting strength from previous ICS/combination treatment, disease severity and current control. Rinse and spit after each dose.

Benefit may develop before maximum effect, which can take a week or longer. Labels permit reassessment after about two weeks of inadequate response, including technique/adherence review and supervised strength change. GINA considers gradual step-down after 2–3 months of control without exacerbations; provide an action plan and monitor. Do not completely withdraw ICS except a clinician-directed diagnostic trial. A dose-category table does not establish potency equivalence between devices.

If a dose is missed, take the next at the usual time; do not double. Hepatic disease may increase exposure and requires close monitoring. Formal renal PK studies are absent; these labels do not give a renal adjustment algorithm. Use the lowest effective maintenance strength with regular review.

Primary treatment of status asthmaticus/acute episodes requiring intensive care and product-ingredient hypersensitivity are contraindicated. Diskus, Wixela and AirDuo powders contain lactose with milk proteins and contraindicate severe milk-protein allergy. Advair HFA does not carry that milk-protein contraindication; check its actual ingredients rather than applying powder rules to all inhalers. Severe milk-protein allergy is distinct from lactose intolerance.

No boxed warning appears in the selected current combination labels. FDA’s 2017 class review removed the combination ICS/LABA asthma-death box after required safety trials, while preserving serious-event warnings for LABA alone in asthma. Combination trials did not establish absence of every risk. Do not reproduce the historical combination box as current or imply salmeterol monotherapy is safe.

Reported effects include upper-respiratory/throat symptoms, candidiasis, hoarseness, headache, cough and musculoskeletal complaints; profile/rates differ by device and population. Serious systemic steroid, cardiac, allergic and respiratory reactions are described above. Excess salmeterol can cause tachyarrhythmia/QTc prolongation, hypokalemia, seizures or cardiac arrest; repeated excessive ICS can cause hypercorticism. Stop excess dosing and seek urgent medical/Poison Help guidance (U.S. 1-800-222-1222); overdose requires supportive care and cardiac monitoring.

Human data are insufficient to define all fetal risk; poorly controlled asthma itself increases maternal/perinatal complications. Review treatment and maintain control during pregnancy rather than stopping without a plan. Human milk data for both components and infant/milk-production effects are unavailable; low inhaled plasma levels suggest low milk exposure, but this is an inference. Balance breastfeeding benefit with maternal need and potential infant risk.

Diskus/Wixela asthma is established at ≥4, with only 100/50 twice daily for ages 4–11. HFA/RespiClick asthma is established at ≥12; studies in younger children do not establish approval. Monitor growth and titrate to the lowest effective strength. Older adults warrant cardiovascular caution; COPD populations showed more severe adverse events/pneumonia with older age. The HFA label advises cautious low-end selection; no universal automatic age-based dose conversion exists.

Both components are predominantly hepatically metabolized; liver dysfunction may increase accumulation, so monitor closely. Formal product renal/hepatic PK studies are limited or absent, and no validated renal/hepatic dose-reduction formula is given. Do not equate missing studies with proven unchanged exposure.

Fluticasone propionate activates glucocorticoid signaling and suppresses inflammatory cellular/mediator responses. Salmeterol stimulates beta₂ receptors, increasing cyclic AMP and relaxing bronchial smooth muscle. Maintenance bronchodilation accompanies ICS anti-inflammatory treatment; salmeterol does not replace the ICS.

Systemic exposure

Inhaled lung absorption contributes to exposure; swallowed fluticasone oral bioavailability is negligible because of incomplete absorption/first-pass metabolism. Device and technique influence exposure.

Metabolism

Both are CYP3A4 substrates; interaction-driven accumulation can cause systemic toxicity.

Half-life · product-specific

Advair inhaled fluticasone estimates average ~5.6 hours; AirDuo estimates ~10.8 hours for fluticasone and ~12.6 hours for salmeterol. Advair labels do not calculate inhaled salmeterol terminal half-life.

Interpretation

Do not treat the salmeterol xinafoate salt moiety’s half-life as the active drug duration or use these PK estimates to set inhalation frequency.

Review symptom control, reliever use, exacerbations, adherence, technique and lung function. Assess oral candidiasis, growth, eye symptoms and systemic steroid effects. Bone-density evaluation is recommended before and periodically during Diskus/Wixela COPD treatment; other bone-risk patients need clinical review. Consider glucose/potassium or cardiac assessment when risks, interacting therapy or symptoms warrant. Review infection/immune status and systemic-steroid withdrawal.

Use regularly at prescribed doses; rinse and spit, and keep a separate reliever with a written action plan. Do not take extra doses if powder is not tasted. Check counters/refill before running out. Sudden post-dose wheezing, swelling, severe breathlessness, chest pain or failure of the rescue plan requires urgent/emergency evaluation. Report thrush, vision changes, fever/infection exposure and adrenal symptoms. Technique and orientation differ across devices.

Advair Diskus 250/50 mcg is the representative product. This profile covers Diskus, HFA, Wixela Inhub and AirDuo RespiClick; it excludes AirDuo Digihaler, other generics and non-U.S. devices unless separately verified. Do not confuse salmeterol combinations with fluticasone/vilanterol or fluticasone/formoterol.

Diskus/Wixela: 20–25°C, dry and protected from heat/sun; retain unopened foil until first use and discard one month after opening or counter zero. HFA: 20–25°C, mouthpiece down; discard at counter zero, do not puncture/burn or expose above 120°F. AirDuo: 15–25°C, dry, foil until use; discard at 30 days after opening, counter zero or expiration, whichever first. Follow label excursion limits and device cleaning instructions; do not wash powders or interchange HFA actuator/canister products.